Genentech/ImmunoGen HER2-targeted drug T-DM1 crosses finish line early in US
This article was originally published in Scrip
Executive Summary
A few days ahead of schedule, the US FDA on 22 February granted its OK to Genentech's and ImmunoGen's antibody-drug conjugate (ADC) T-DM1 (ado-trastuzumab emtansine), which will be marketed under the brand name Kadcyla, as a treatment for patients with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy.